Background: Acute exacerbations of chronic obstructive pulmonary disease (AE-COPD) are related to high mortality, especially in hospitalized patients. Predictors for severe outcomes are still not sufficiently defined. Objectives: To assess the mortality rate and identify potential determinants of mortality in a cohort of patients hospitalized for AE-COPD. Methods: A retrospective, observational cohort study including all consecutive patients admitted between January 1, 2009, and April 1, 2010, for AE-COPD. Potential predictors were assessed at initial presentation at the emergency room. The primary outcome was mortality during 1-year follow-up. Univariate and multivariate time-to-event analyses using Cox proportional hazard models were employed for statistical analysis. Results: A total of 260 patients were enrolled in this study. Mean age was 70.5 ± 10.8 years, 50.0% were male and 63.4% had severe COPD. The in-hospital mortality rate was 5.8% and the 1-year mortality rate was 27.7%. Independent risk factors for mortality were age [hazard ratio (HR) = 1.04; 95% confidence interval (CI) = 1.01–1.07], male sex (HR = 2.00; 95% CI = 1.15–3.48), prior hospitalization for AE-COPD in the last 2 years (HR = 2.56; 95% CI = 1.52–4.30), prior recorded congestive heart failure (HR = 1.75; 95% CI = 1.03–2.97), Pac o2 ≥6.0 kPa (HR = 2.90; 95% CI = 1.65–5.09) and urea ≥8.0 mmol/l (HR = 2.38; 95% CI = 1.42–3.99) at admission. Conclusions: Age, male sex, prior hospitalization for AE-COPD in the last 2 years, prior recorded congestive heart failure, hypercapnia and elevated levels of urea at hospital admission are independent predictors of mortality within the first year after admission.

Keywords:
Chronic obstructive pulmonary disease, Exacerbation, Predictor, Mortality, Gender
1.
Hurd S: The impact of COPD on lung health worldwide: epidemiology and incidence. Chest 2000;117:1S–4S.
2.
Mannino DM, Watt G, Hole D, Gillis C, Hart C, McConnachie A, Davey Smith G, Upton M, Hawthorne V, Sin DD, Man SF, Van Eeden S, Mapel DW, Vestbo J: The natural history of chronic obstructive pulmonary disease. Eur Respir J 2006;27:627–643.
3.
Rutten-van Molken MP, Postma MJ, Joore MA, Van Genugten ML, Leidl R, Jager JC: Current and future medical costs of asthma and chronic obstructive pulmonary disease in The Netherlands. Respir Med 1999;93:779–787.
4.
Global Initiative for Chronic Obstructive Lung Disease: Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease (updated 2010). http://www.goldcopd.com.
5.
Roberts CM, Lowe D, Bucknall CE, Ryland I, Kelly Y, Pearson MG: Clinical audit indicators of outcome following admission to hospital with acute exacerbation of chronic obstructive pulmonary disease. Thorax 2002;57:137–141.
6.
Almagro P, Calbo E, Ochoa de Echaguen A, Barreiro B, Quintana S, Heredia JL, Garau J: Mortality after hospitalization for COPD. Chest 2002;121:1441–1448.
7.
Groenewegen KH, Schols AM, Wouters EF: Mortality and mortality-related factors after hospitalization for acute exacerbation of COPD. Chest 2003;124:459–467.
8.
Patil SP, Krishnan JA, Lechtzin N, Diette GB: In-hospital mortality following acute exacerbations of chronic obstructive pulmonary disease. Arch Intern Med 2003;163:1180–1186.
9.
Wang Q, Bourbeau J: Outcomes and health-related quality of life following hospitalization for an acute exacerbation of COPD. Respirology 2005;10:334–340.
10.
Tan WC: Factors associated with outcomes of acute exacerbations of chronic obstructive pulmonary disease. COPD 2004;1:225–247.
11.
Yang S, Tan KL, Devanand A, Fook-Chong S, Eng P: Acute exacerbation of COPD requiring admission to the intensive care unit. Respirology 2004;9:543–549.
12.
Gunen H, Hacievliyagil SS, Kosar F, Mutlu LC, Gulbas G, Pehlivan E, Sahin I, Kizkin O: Factors affecting survival of hospitalised patients with COPD. Eur Respir J 2005;26:234–241.
13.
Fuso L, Incalzi RA, Pistelli R, Muzzolon R, Valente S, Pagliari G, Gliozzi F, Ciappi G: Predicting mortality of patients hospitalized for acutely exacerbated chronic obstructive pulmonary disease. Am J Med 1995;98:272–277.
14.
Seneff MG, Wagner DP, Wagner RP, Zimmerman JE, Knaus WA: Hospital and 1-year survival of patients admitted to intensive care units with acute exacerbation of chronic obstructive pulmonary disease. JAMA 1995;274:1852–1857.
15.
Connors AF Jr, Dawson NV, Thomas C, Harrell FE Jr, Desbiens N, Fulkerson WJ, Kussin P, Bellamy P, Goldman L, Knaus WA: Outcomes following acute exacerbation of severe chronic obstructive lung disease: The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments). Am J Respir Crit Care Med 1996;154:959–967.
16.
Antonelli Incalzi R, Fuso L, De Rosa M, Forastiere F, Rapiti E, Nardecchia B, Pistelli R: Co-morbidity contributes to predict mortality of patients with chronic obstructive pulmonary disease. Eur Respir J 1997;10:2794–2800.
17.
Soler-Cataluna JJ, Martinez-Garcia MA, Roman Sanchez P, Salcedo E, Navarro M, Ochando R: Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 2005;60:925–931.
18.
Matkovic Z, Huerta A, Soler N, Domingo R, Gabarrus A, Torres A, Miravitlles M: Predictors of adverse outcome in patients hospitalised for exacerbation of chronic obstructive pulmonary disease. Respiration 2012;84:17–26.
19.
Global Initiative for Chronic Obstructive Lung Disease: Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease (updated 2011). http://www.goldcopd.com.
20.
Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA: Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987;106:196–204.
21.
McGhan R, Radcliff T, Fish R, Sutherland ER, Welsh C, Make B: Predictors of rehospitalization and death after a severe exacerbation of COPD. Chest 2007;132:1748–1755.
22.
Zvezdin B, Milutinov S, Kojicic M, Hadnadjev M, Hromis S, Markovic M, Gajic O: A postmortem analysis of major causes of early death in patients hospitalized with COPD exacerbation. Chest 2009;136:376–380.
23.
Hurst JR, Wedzicha JA: Management and prevention of chronic obstructive pulmonary disease exacerbations: a state of the art review. BMC Med 2009;7:40.
24.
Faustini A, Marino C, D’Ippoliti D, Forastiere F, Belleudi V, Perucci CA: The impact on risk-factor analysis of different mortality outcomes in COPD patients. Eur Respir J 2008;32:629–636.
25.
Garcia-Aymerich J, Serra Pons I, Mannino DM, Maas AK, Miller DP, Davis KJ: Lung function impairment, COPD hospitalisations and subsequent mortality. Thorax 2011;66:585–590.
26.
Hoogendoorn M, Hoogenveen RT, Rutten-van Molken MP, Vestbo J, Feenstra TL: Case fatality of COPD exacerbations: a meta-analysis and statistical modelling approach. Eur Respir J 2011;37:508–515.
27.
Charlson ME, Pompei P, Ales KL, MacKenzie CR: A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373–383.
28.
Brekke PH, Omland T, Holmedal SH, Smith P, Soyseth V: Troponin t elevation and long-term mortality after chronic obstructive pulmonary disease exacerbation. Eur Respir J 2008;31:563–570.
29.
Fruchter O, Yigla M: Cardiac troponin-I predicts long-term mortality in chronic obstructive pulmonary disease. COPD 2009;6:155–161.
30.
Lieberman D, Lieberman D, Gelfer Y, Varshavsky R, Dvoskin B, Leinonen M, Friedman MG: Pneumonic vs nonpneumonic acute exacerbations of COPD. Chest 2002;122:1264–1270.
31.
Rutten FH, Cramer MJ, Lammers JW, Grobbee DE, Hoes AW: Heart failure and chronic obstructive pulmonary disease: an ignored combination? Eur J Heart Fail 2006;8:706–711.
32.
Janssen DJ, Spruit MA, Uszko-Lencer NH, Schols JM, Wouters EF: Symptoms, comorbidities, and health care in advanced chronic obstructive pulmonary disease or chronic heart failure. J Palliat Med 2011;14:735–743.
33.
Abroug F, Ouanes-Besbes L, Nciri N, Sellami N, Addad F, Hamda KB, Amor AB, Najjar MF, Knani J: Association of left-heart dysfunction with severe exacerbation of chronic obstructive pulmonary disease: diagnostic performance of cardiac biomarkers. Am J Respir Crit Care Med 2006;174:990–996.
34.
Tung RH, Camargo CA Jr, Krauser D, Anwaruddin S, Baggish A, Chen A, Januzzi JL Jr: Amino-terminal pro-brain natriuretic peptide for the diagnosis of acute heart failure in patients with previous obstructive airway disease. Ann Emerg Med 2006;48:66–74.
35.
Gray-Donald K, Gibbons L, Shapiro SH, Macklem PT, Martin JG: Nutritional status and mortality in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1996;153:961–966.
36.
Ai-Ping C, Lee KH, Lim TK: In-hospital and 5-year mortality of patients treated in the ICU for acute exacerbation of COPD: a retrospective study. Chest 2005;128:518–524.
37.
Lim WS, van der Eerden MM, Laing R, Boersma WG, Karalus N, Town GI, Lewis SA, Macfarlane JT: Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003;58:377–382.
38.
Wouters EF: Management of severe COPD. Lancet 2004;364:883–895.
39.
De Angelis C, Perrone A, Ferri C, Piccoli A, Bellini C, D’Amelio R, Santucci A, Balsano F: Oxygen administration increases plasma digoxin-like substance and renal sodium excretion in chronic hypoxic patients. Am J Nephrol 1993;13:173–177.
40.
Sharkey RA, Mulloy EM, Kilgallen IA, O’Neill SJ: Renal functional reserve in patients with severe chronic obstructive pulmonary disease. Thorax 1997;52:411–415.
41.
Ucgun I, Oztuna F, Dagli CE, Yildirim H, Bal C: Relationship of metabolic alkalosis, azotemia and morbidity in patients with chronic obstructive pulmonary disease and hypercapnia. Respiration 2008;76:270–274.
42.
Cazzola M, MacNee W, Martinez FJ, Rabe KF, Franciosi LG, Barnes PJ, Brusasco V, Burge PS, Calverley PM, Celli BR, Jones PW, Mahler DA, Make B, Miravitlles M, Page CP, Palange P, Parr D, Pistolesi M, Rennard SI, Rutten-van Molken MP, Stockley R, Sullivan SD, Wedzicha JA, Wouters EF, American Thoracic Society, European Respiratory Society Task Force on outcomes of COPD: Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J 2008;31:416–469.
43.
Hallin R, Gudmundsson G, Suppli Ulrik C, Nieminen MM, Gislason T, Lindberg E, Brondum E, Aine T, Bakke P, Janson C: Nutritional status and long-term mortality in hospitalised patients with chronic obstructive pulmonary disease (COPD). Respir Med 2007;101:1954–1960.
44.
Landbo C, Prescott E, Lange P, Vestbo J, Almdal TP: Prognostic value of nutritional status in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999;160:1856–1861.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.